Özlem Türeci
厄兹莱姆·图雷奇
MD
Co-Founder & Chief Medical Officer, BioNTech SE拜恩泰科联合创始人兼首席医疗官
👥Biography 个人简介
Özlem Türeci is co-founder and Chief Medical Officer of BioNTech SE, and a world leader in cancer immunotherapy and personalized mRNA cancer vaccines. She has driven clinical translation of BioNTech's iNeST platform from concept to pivotal trials, and co-developed BNT111, BNT113, and mRNA-4157/V940 with major academic and industry partners.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Clinical Development of Personalized mRNA Cancer Vaccines
Led the medical and clinical strategy for BioNTech's individualized neoantigen vaccine program, overseeing phase 1 and 2 trials across melanoma, lung, and colorectal cancers, establishing proof-of-concept for mRNA neoantigen immunotherapy.
Tumor Antigen Discovery and BioNTech Pipeline
Co-pioneered systematic identification of tumor-associated antigens using genomics and proteomics, providing the scientific foundation for BioNTech's fixed-neoantigen vaccines BNT111 (melanoma) and BNT113 (HPV+ head and neck cancer).
mRNA COVID-19 Vaccine and Global Health Impact
Co-led development of BNT162b2 (Comirnaty/Pfizer-BioNTech COVID-19 vaccine), validating mRNA LNP platform at global scale and accelerating credibility for mRNA cancer vaccine clinical programs.
Representative Works 代表性著作
Individualized vaccines of RNA neoepitopes as immunotherapy for patients with melanoma
Nature (2017)
Co-primary author; first clinical demonstration of individualized mRNA neoantigen vaccines generating polyfunctional neoepitope-specific T cell immunity in melanoma patients.
Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates
New England Journal of Medicine (2020)
Phase 1/2 data for BNT162 vaccine candidates; established the mRNA-LNP platform's safety and immunogenicity profile underpinning oncology vaccine development.
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
Nature (2022)
Demonstrated BNT111 fixed-neoantigen mRNA vaccine elicited robust and durable T cell responses in anti-PD-1 pretreated melanoma patients, with objective tumor responses observed.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
关注 厄兹莱姆·图雷奇 的研究动态
Follow Özlem Türeci's research updates
留下邮箱，当我们发布与 Özlem Türeci（BioNTech SE / University Medical Center of the Johannes Gutenberg University Mainz）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment